Table I.
Clinical characteristics of control subjects and DCM patients.
| Controls (n=8) | DCM patients (n=8) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| Sex | M | M | M | M | F | M | M | M | M | M | M | M | F | M | M | M |
| Age (years) | 32 | 38 | 35 | 35 | 61 | 60 | 46 | 35 | 33 | 40 | 33 | 36 | 63 | 61 | 47 | 34 |
| SBP (mmHg) | 110 | 120 | 112 | 118 | 124 | 122 | 126 | 118 | 140 | 120 | 110 | 108 | 104 | 102 | 102 | 124 |
| DBP (mmHg) | 72 | 74 | 70 | 74 | 74 | 80 | 82 | 72 | 90 | 80 | 70 | 72 | 76 | 70 | 86 | 78 |
| Heart rate (rpm) | 66 | 68 | 72 | 65 | 73 | 67 | 76 | 74 | 105 | 86 | 98 | 85 | 72 | 105 | 78 | 90 |
| LVED (mm) | 46 | 44 | 41 | 46 | 44 | 47 | 43 | 44 | 56 | 63 | 67 | 78 | 84 | 62 | 68 | 75 |
| LVEF (%) | 68 | 61 | 68 | 66 | 65 | 73 | 77 | 68 | 42 | 26 | 20 | 16 | 19 | 25 | 30 | 27 |
| NT-proBNP (pg/ml) | 70 | 82 | 60 | 84 | 96 | 90 | 88 | 78 | 5,400 | 6,630 | 1,470 | 2,450 | 2,980 | 1,760 | 2,530 | 2,228 |
| NYHA class | – | – | – | – | – | – | – | – | IV | III | III | III | IV | IV | IV | III |
DCM, dilated cardiomyopathy; M, male; F, female; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVED, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association.